Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) Income from Continuing Operations: 2012-2024

Historic Income from Continuing Operations for BioLineRx (BLRX) over the last 13 years, with Dec 2024 value amounting to -$11.3 million.

  • BioLineRx's Income from Continuing Operations rose 45.04% to -$2.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$7.7 million, marking a year-over-year increase of 80.04%. This contributed to the annual value of -$11.3 million for FY2024, which is 76.25% up from last year.
  • According to the latest figures from FY2024, BioLineRx's Income from Continuing Operations is -$11.3 million, which was up 76.25% from -$47.5 million recorded in FY2023.
  • Over the past 5 years, BioLineRx's Income from Continuing Operations peaked at -$11.3 million during FY2024, and registered a low of -$47.5 million during FY2023.
  • Its 3-year average for Income from Continuing Operations is -$28.6 million, with a median of -$27.0 million in 2022.
  • As far as peak fluctuations go, BioLineRx's Income from Continuing Operations plummeted by 76.03% in 2023, and later surged by 76.25% in 2024.
  • BioLineRx's Income from Continuing Operations (Yearly) stood at -$21.3 million in 2020, then dropped by 11.61% to -$23.8 million in 2021, then decreased by 13.58% to -$27.0 million in 2022, then plummeted by 76.03% to -$47.5 million in 2023, then soared by 76.25% to -$11.3 million in 2024.